Vitalhub (VHI) Q3 2024 earnings summary

Executive summary

• Achieved 25% year-over-year revenue growth to CAD 16.5 million in Q3 2024, with ARR up 25% to CAD 53.5 million.

• Adjusted EBITDA rose 33% year-over-year to CAD 4.6 million, representing a 28% margin.

• Completed two strategic acquisitions post-quarter, expanding the patient flow suite and international presence, raising pro forma ARR to CAD 68 million.

• Integration of acquisitions is underway, with a focus on maintaining margins and scaling free cash flow.

• Nine-month revenue increased 23% year-over-year to CAD 48.0 million, with net income before taxes up 71% to CAD 5.7 million.

Financial highlights

• Q3 2024 total revenue was CAD 16.5 million, up 25% year-over-year.

• Term license maintenance and support revenue reached CAD 13.9 million, up 28% year-over-year, comprising 84% of total revenue.

• Annual recurring revenue (ARR) at quarter-end was CAD 53.5 million, up 25% year-over-year and 4% sequentially.

• Gross margin was 81% of revenue, compared to 82% in Q3 2023.

• Net income before taxes was CAD 2.4 million, up 30% year-over-year; Adjusted EBITDA was CAD 4.6 million, with a 28% margin.

• Cash on hand as of September 30, 2024, was CAD 81.4 million, up from CAD 33.5 million at year-end 2023, with no debt.

Outlook and guidance

• Expect steady growth in ARR and service work into year-end, with a strong backlog extending into 2025 and 2026.

• Integration of recent acquisitions may temporarily impact EBITDA margins, but plans are in place to restore and grow margins.

• M&A pipeline remains active, with a disciplined approach to future acquisitions and continued growth through organic expansion.